Nucleic acid delivery vehicle and uses thereof

US9545421B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9545421-B2
Application numberUS-77347810-A
CountryUS
Kind codeB2
Filing dateMay 4, 2010
Priority dateMay 4, 2010
Publication dateJan 17, 2017
Grant dateJan 17, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A nucleic acid-delivery vehicle for delivering nucleic acids to target cells is provided. The nucleic acid-delivery vehicle comprises a plurality of nanoparticles; and a plurality of nucleic acids. The nanoparticles and the nucleic acids are agglomerated to form a nucleic acid-granulation particle having a dimension of at least 5 nm. Methods of making the nucleic acid-delivery vehicle and kits comprising nucleic acid-delivery vehicle are also provided.

First claim

Opening claim text (preview).

The invention claimed is: 1. A nucleic acid-delivery vehicle comprising: a plurality of nanoparticles; and a plurality of double-stranded nucleic acids, wherein the nanoparticles and the double-stranded nucleic acids are agglomerated to form a nucleic acid-granulation particle, wherein the longest dimension of the nucleic acid granulation particle is at least 5 nm wherein the granulation particle comprises the plurality of nanoparticles with a homogenous distribution of the double-stranded nucleic acids, and wherein the granulation particles comprise a mix of nanoparticles with covalently attached signal moieties and nanoparticles devoid of signal moieties. 2. The nucleic acid-delivery vehicle of claim 1 , wherein the longest dimension is in a range from about 5 nm to 10 μm. 3. The nucleic acid-delivery vehicle of claim 1 , wherein the nanoparticles are selected from metal nanoparticles, metal oxide nanoparticles, metal nitride nanoparticles, metal carbides nanoparticles, and combinations thereof. 4. The nucleic acid-delivery vehicle of claim 1 , wherein the nanoparticles are selected from gold nanoparticles, iron nanoparticles, iron oxide nanoparticles, titanium nanoparticles, titanium oxide nanoparticles, silica nanoparticles, alumina nanoparticles, zinc nanoparticles, zinc oxide nanoparticles, tin nanoparticles, tin oxide nanoparticles, copper nanoparticles, copper oxide nanoparticles, hafnium nanoparticles, hafnia nanoparticles, yttria nanoparticles, yttrium aluminum garnet nanoparticles, magnesium aluminate spinel nanoparticles, magnesium oxide nanoparticles, calcium carbonate nanoparticles, calcium phosphate nanoparticles, diamond nanoparticles, silver nanoparticles, and platinum nanoparticles. 5. The nucleic acid-delivery vehicle of claim 1 , wherein the nanoparticles comprise one or more specific primers attached to the nanoparticles. 6. The nucleic acid-delivery vehicle of claim 1 , wherein the nucleic acids are deoxyribonucleic acids or ribonucleic acids. 7. The nucleic acid-delivery vehicle of claim 1 , wherein the nucleic acids comprise one or more nuclease-resistant bases or nucleotide analogs. 8. The nucleic acid-delivery vehicle of claim 1 , wherein the nucleic acids code for an antigenic polypeptide, or a protein. 9. A deoxyribonucleic acid vaccine comprising the nucleic acid-delivery vehicle of claim 8 , wherein the nucleic acids are deoxyribonucleic acids. 10. A nucleic acid-delivery vehicle comprising: a plurality of nanoparticles; and a plurality of double stranded nucleic acids, wherein the nanoparticles and the double stranded nucleic acids are agglomerated to form a double stranded nucleic acid-granulation particle having a longest dimension of at least 5 nm and wherein the double stranded nucleic acid-granulation particle comprises nucleic acids that are only double stranded.

Assignees

Inventors

Classifications

  • Immunostimulants · CPC title

  • the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title

  • Iron; Compounds thereof · CPC title

  • Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

  • DNA (RNA) vaccination · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9545421B2 cover?
A nucleic acid-delivery vehicle for delivering nucleic acids to target cells is provided. The nucleic acid-delivery vehicle comprises a plurality of nanoparticles; and a plurality of nucleic acids. The nanoparticles and the nucleic acids are agglomerated to form a nucleic acid-granulation particle having a dimension of at least 5 nm. Methods of making the nucleic acid-delivery vehicle and kits …
Who is the assignee on this patent?
Nelson John Richard, Yosenick Timothy James, Gen Electric
What technology area does this patent fall under?
Primary CPC classification A61K31/7105. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).